Phosphatase and tensin homolog deleted on chromosome ten (PTEN ) is a human suppressor gene. Its protein product is a bispecific phosphatase playing the complex role in the cell cycle regulating processes and apoptosis by the mechanism of signal transduction into the cell via tyrosine kinase B signaling pathway (PI3K/Akt/mTOR). Reduction or loss of PTEN function is implicated in the pathogenesis of many malignancies, including colorectal cancer. A gradual decrease in the function of PTEN in the sequence of transformations: normal tissue-polyp-adenocarcinoma -disseminated cancer was indicated. The relation between the PTEN loss and the higher clinical severity of colorectal cancer was observed, i.a. higher TNM status and higher tendency to form metastases, leading in some of the studies to shortened patients survival during the observation period. The potential predictive value of the PTEN function loss for the EGFR-targeted therapy in patients with advanced colorectal cancer is the subject of controversy. The potential application of PTEN assessment in clinical practice as a prognostic and/or predictive factor requires further well-designed prospective studies on larger patient population, using the unified methodology.
INTRODUcTION
In Poland, colorectal cancer (CRC) is the 2 nd common cause of cancer-related deaths in males and the 3 rd one in females in 2013. In 2013, CRC was detected in 15,899 people [1] . The forecasts for 2015 indicate an increase in the incidence to 18 ,286 per year [2] .
The aetiology of CRC is multifactorial and the oncogenesis is a multistep process. Studies conducted in experimental models allowed Fearon and Vogelstein to formulate the concept of neoplastic transformation in 1990, whereby the CRC development involves an alternating sequence from normal epithelium to adenoma, and thereafter a gradual increase of lesion size and invasiveness, finally effecting in cancer development [3] . An important role in adenoma -carcinoma transformation sequence is played by molecular processes such as DNA repair defects, PTEN is the second most common human gene undergoing somatic mutations (after the TP53) [4] . Loss of PTEN expression may occur as a result of various genomic changes, including somatic mutations, chromosomal deletion or epigenetic changes such as promoter region hypermethylation [5, 6] .
Decrease or loss of PTEN function are described in the course of many medical condition as well as malignant tumours. Germline mutations of PTEN gene underlie some rare autosomal dominant diseases: the Cowden syndrome, Bannayan-RileyRuvalcaba syndrome and Proteus syndrome, which are known as PTEN hamartoma tumor syndromes (PHTS) [7] . In turn, the somatic mutations, deletions or epigenetic changes of the PTEN gene are involved in the pathogenesis of many malignant tumours: CRC [5] [6] [7] , stomach cancer [8] , pancreatic cancer [9] , hepatocellular carcinoma [10] , thyroid cancer [11] , prostate [12] , breast [13] and ovarian cancer [14] , endometrial cancer [15] , lung cancer [16, 17] , renal cell carcinoma [18] , melanoma [19] and glioblastoma [20] . Data obtained from studies on human tumor cell lines and animal models indicate that the effects of PTEN inactivation are specific for the tissue in which the lesion occurs [21] .
PTEN -THE MEcHANIsMs OF AcTION
The lipid phosphatase activity is the best known PTEN protein property and determines its tumour suppressor function. PTEN is currently the only known lipid phosphatase acting as the phosphatidylinositide 3-kinase (PI3K) agonist [6] . PTEN protein In actively dividing cells, the PIP3 level is high and the Akt kinase complex is activated by phosphorylation. The initiation of apoptosis is associated with the decrease of PIP3 levels and Akt kinase dephosphorylation under high PTEN concentration [13, 22] . The functional PTEN deficit leads to the PI3K activation and continuous Akt kinase pathway stimulation, resulting in the promotion of carcinogenesis processes, such as apoptosis inhibition, cellular growth independent from growth factors, lack of response to growth inhibitors, unlimited division potential of cells, genomic instability, angiogenesis stimulation, cell migration, surrounding tissue invasion and metastasis [6, 23] .
On the other hand, PTEN protein also exhibits poor phosphatase properties to some proteins, including the PTEN protein and growth factors receptors [23] . PTEN affects the cell functions also in mechanisms that are partially independent of its phosphatase activity.
PTEN function enables the maintenance of normal tissues architecture by affecting the intercellular connections stabilisation, cell polarity and migration [24] . The inactivation of PTEN in combination with agents in tumour micro-environment, such
as TNF-α, may increase the CRC invasiveness [25] .
THE PTEN EXPREssION AND THE sTAGE OF cARcINOGENEsIs
There is considerable evidence indicating a gradual reduction of PTEN expression in the sequence of transformations:
normal tissue-polyp-adenocarcinoma-distant metastases [5, [26] [27] [28] . There was no difference in the PTEN expression intensity between polyps appearing synchronously with CRC and polyps occurring as the single colonic lesion [29] .
On the other hand, Hsu et al. 
PTEN AND cANcER ADVANcEMENT
There are abundant data demonstrating that reduced PTEN expression may be associated with increased severity of the disease, manifested by higher TNM and Dukes' stage [22, 28, 31] , greater invasion depth [22] , larger tumour size [22, 30] , lower histological grade [32, 33] , more frequent lymph node involvement [22, 34] , blood vessels infiltration [30] , distant metastases [33] and, as a consequence, shorter patients survival during follow-up [22] . The relation between the loss of PTEN expression and greater clinical advancement and high CEA antigen concentration was indicated [5] . There are also a few reports suggesting that a PTEN expression reduction may be an independent predictor of the local recurrence when the regression model was used [29] .
Studies on experimental models show that PTEN participates in the CRC cell polarity regulation, affecting their migration, invasiveness and metastatic potential. However, it is not the factor that autonomously initiates processes which lead to the formation of metastases [24] . 
PTEN AND EGFR-TARGETED THERAPY OUTcOMEs
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